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OBJECTIVES We sought to determine the incidence of cholesterol embolization syndrome (CES) as a
complication of cardiac catheterization and to identify risk factors associated with this disease.
BACKGROUND Cholesterol embolization syndrome is a systemic disease caused by distal showering of
cholesterol crystals after angiography, major vessel surgery, or thrombolysis.
METHODS We prospectively evaluated a total of 1,786 consecutive patients 40 years of age and older,
who underwent left-heart catheterization at 11 participating hospitals. The diagnosis of CES
was made when patients had peripheral cutaneous involvement (livedo reticularis, blue toe
syndrome, and digital gangrene) or renal dysfunction.
RESULTS Twenty-five patients (1.4%) were diagnosed as having CES. Twelve patients (48%) had
cutaneous signs, and 16 patients (64%) had renal insufficiency. Eosinophil counts were
significantly higher in CES patients than in non-CES patients before and after cardiac
catheterization. The in-hospital mortality rate was 16.0% (4 patients), which was significantly
higher than that without CES (0.5%, p  0.01). All four patients with CES who died after
cardiac catheterization had progressive renal dysfunction. The incidence of CES increased in
patients with atherosclerotic disease, hypertension, a history of smoking, and the elevation of
baseline plasma C-reactive protein (CRP) by univariate analysis. The femoral approach did
not increase the incidence, suggesting a possibility that the ascending aorta may be a potential
embolic source. As an independent predictor of CES, multivariate regression analysis
identified only the elevation of pre-procedural CRP levels (odds ratio 4.6, p  0.01).
CONCLUSIONS Cholesterol embolization syndrome is a relatively rare but serious complication after cardiac
catheterization. Elevated plasma levels of pre-procedural CRP are associated with subsequent
CES in patients who undergo vascular procedures. (J Am Coll Cardiol 2003;42:211–6)
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Cholesterol embolization syndrome (CES) is a systemic
atheroembolism involving brain, eyes, kidneys, and extrem-
ities, caused by distal showering of cholesterol crystals from
aortic atheromatous plaques (1). Since the 1960s, various
investigators have reported cases of CES such as blue toe
syndrome or acute renal failure as a complication of angiog-
raphy, major vessel surgery, or thrombolytic therapy (2–11).
It has been reported that eosinophil counts increase during
the active phase of CES cases (12,13).
See page 217
Clinical consequences of CES vary considerably, from
being completely asymptomatic to presenting acute multi-
organ failure, including progressive renal failure or cutane-
ous involvement, with a mortality rate as high as 70% to
90% (14). However, the actual incidence of this syndrome
remains uncertain. Estimates of the incidence of CES after
vascular procedures have ranged from 0.15% in clinical
studies (5) to 25% to 30% in pathologic series (3). Clinical
studies probably underestimated the incidence because only
a minority of patients can be clinically recognized. There-
fore, despite the importance of this disease as a complication
of percutaneous diagnostic and interventional procedures,
the clinical characteristics of CES remain uncertain. Quan-
tification of the risk factors for post-catheterization CES is
critically important to both patients and physicians. How-
ever, no studies have comprehensively examined both clin-
ical and therapeutic variables that can be applied to estimate
the risk of CES in patients undergoing cardiac catheteriza-
tion.
Therefore, the goals of the present study were: 1) to
determine the incidence of CES after cardiac catheteriza-
tion; and 2) to determine the risk factors that are indepen-
dently associated with CES as complications after cardiac
catheterization. For this purpose, we prospectively examined
the presence of cutaneous findings, and we compared serum
creatinine levels and blood eosinophil counts between pre-
and post-procedure.
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METHODS
Study population. A total of 1,786 consecutive patients, 40
years old or older (mean, 65  10 years; range, 40–92
years), who underwent left cardiac catheterization between
June 1, 1998, and September 30, 1999, in 11 participating
hospitals, were prospectively evaluated to identify CES.
There were 1,169 men and 617 women. For each patient,
baseline demographic, clinical, procedural, and outcome
data were collected by use of a standardized data collection
form by the participating hospitals. Serum creatinine levels,
blood cell counts including white blood cells and eosino-
phils, and C-reactive proteins (CRPs) were measured before
cardiac catheterization. Serum creatinine levels were mea-
sured in all patients, blood cell counts in 94% of patients,
and CRP in 77% of patients. All patients provided informed
consent, and the study protocol was approved by the ethical
committees of participating hospitals.
Definition of CES. Cutaneous signs of CES including
livedo reticularis, blue toe syndrome, and digital gangrene
were recorded at the time of the initial procedure and two
weeks after cardiac catheterization. Serum creatinine levels
were also recorded before and two weeks following
catheterization.
“Definite CES” was defined if the patients had cutaneous
signs including livedo reticularis, blue toe syndrome, and
digital gangrene with or without renal impairment. “Possi-
ble CES” was defined if patients had only renal dysfunction
referring to a post-catheterization serum creatinine 1.3
mg/dl and an increase of creatinine level by 50% from the
baseline value two weeks after the procedure without skin
lesions (11,15) (Table 1). In the patients with chronic renal
failure with hemodialysis, CES was diagnosed only in the
presence of the peripheral cutaneous involvement. Several
previous case reports have demonstrated that serum creati-
nine levels increase from a few days to a few months after
the procedures (16–18). Therefore, although we cannot
exactly exclude the possibility of the contribution of contrast
nephrotoxicity, we consider that the increase of creatinine
within several days is probably due to contrast nephrotox-
icity, whereas the increase of creatinine at two weeks
suggests possible CES.
Data collection. Baseline demographic information (in-
cluding age and gender), clinical diagnosis, comorbidities
(cerebrovascular disease, aortic aneurysm, and arteriosclero-
sis obliterans), and atherosclerotic risk factors (hypercholes-
terolemia, history of smoking, hypertension, and diabetes
mellitus) were recorded for each patient. History and/or
vascular study documented acute coronary syndromes, cere-
brovascular disease, aortic aneurysm, and arteriosclerosis
obliterans. Hypercholesterolemia was defined as total cho-
lesterol 220 mg/dl. Hypertension was defined as systolic
blood pressure 140 mm Hg and/or diastolic blood pres-
sure 90 mm Hg. Diabetes was defined as fasting blood
sugar140 mg/dl or blood sugar during a 75-g oral glucose
tolerance test 200 mg/dl. Renal dysfunction was defined
as creatinine clearance levels 50 ml/min/m2 calculated by
the Cockroft-Gault formula. Multivessel disease was de-
fined as 75% stenosis in more than two major epicardial
coronary arteries. Furthermore, left ventricular ejection
fraction (LVEF) was assessed by echocardiography. Coro-
nary interventions included all catheter-based revasculariza-
tion procedures such as balloon angioplasty, stent emplace-
ment, and directional and rotational atherectomy. All
patients had 3,000 to 5,000 U heparin at the beginning of
the procedure. Patients were classified as “anticoagulated”
when heparin or warfarin was continued for more than 24 h
after the procedures. No patient received thrombolytic
agents in the present study. Death and the need for
hemodialysis during hospitalization were recorded.
Statistical analysis. Continuous variables were expressed
as mean  SD. Comparisons between patients with and
without CES were made by use of unpaired t test for
continuous variables and chi-square test for categorical
variables. All variables that were associated with CES with
a value of p  0.05 in univariate analyses were included in
the multivariate models. Odds ratios (ORs) and 95% con-
fidence intervals (CIs) were calculated based on the multiple
logistic regression analysis. All statistical analyses were
performed using the SPSS (SPSS Inc., Chicago, Illinois) or
StatView (SAS Institute, Cary, North Carolina), and p
values  0.05 were considered statistically significant.
Table 2. Incidence of Definite and Possible CES
n (%)
Definite and possible CES 25 1.40
Skin lesion 12 0.67
Renal dysfunction 16 0.90
Both 3 0.17
Definite CES 12 0.67
Possible CES 13 0.73
Abbreviation defined in Table 1.
Abbreviations and Acronyms
AMI  acute myocardial infarction
CES  cholesterol embolization syndrome
CRP  C-reactive protein
Table 1. Diagnostic Criteria of CES
Criteria 1: Peripheral cutaneous involvement
Livedo reticularis
Blue toe syndrome
Digital gangrene
Criteria 2: Acute renal insufficiency (excluded if patients have already
undergone hemodialysis)
Increase in serum creatinine level (mg/dl)
Before catheterization 2 weeks after catheterization
0.8 1.3
0.9 50%
“Definite CES” was defined as the presence of criteria 1 with or without criteria 2.
“Possible CES” was defined as the presence of only criteria 2.
CES  cholesterol embolization syndrome.
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RESULTS
Clinical features of CES. Among 1,786 consecutive pa-
tients, 25 patients were diagnosed as having CES (1.4%).
Twelve of 25 patients had peripheral cutaneous involve-
ment, 16 patients had renal dysfunction, and 3 patients had
both (Table 2). Therefore, 12 patients were diagnosed as
definite CES and 13 patients were possible CES. The
eosinophil counts after the procedure as well as at baseline
were significantly higher in CES patients than in non-CES
patients. The prevalence of post-procedure eosinophilia
(500/l) was also significantly higher in patients with
CES. The in-hospital mortality rate was 16.0% (4 patients)
in patients with CES, which was significantly higher than in
those without CES (0.5%, p  0.01, Table 3). All four
patients underwent coronary intervention. Three out of four
patients had acute myocardial infarction (AMI), and the
other patient with diabetes mellitus had silent ischemia. All
four patients were treated by hemodialysis. However, one
patient with AMI died of CES five months after angiog-
raphy; this patient had progressive deterioration of renal
function owing to CES. Two other patients died of AMI
with acute renal failure seven to eight weeks after the
procedure, in which CES might be attributable to the
progression of renal failure. One patient with silent ischemia
died of non-cardiac cause after seven months. Even though
all patients had interventional procedures, none had their
major complication of cardiac catheterization, including
bleeding or cardiac tamponade.
Comparison of CES with and without renal dysfunction.
Baseline serum creatinine concentration and eosinophil
counts were comparable between CES patients with and
without renal dysfunction. The mean serum creatinine
concentration significantly increased, from 1.6 to 3.3 mg/dl
in 16 patients with renal dysfunction (Table 4). The
eosinophil counts significantly increased from 220 to 535
cells/l in patients with renal dysfunction, whereas nine
patients of CES without renal dysfunction did not show the
increase (from 302 to 339 cells/l). All four patients who
died after cardiac catheterization showed progressive acute
renal failure (Table 4). The remaining 21 patients were all
discharged from the hospital.
Risk factors for the occurrence of CES. We performed a
univariate analysis to determine the association between
patient variables and the occurrence of postprocedure CES
(Table 5). Acute coronary syndromes and multivessel cor-
onary artery disease were univariate predictors of CES.
Hypertension, smoking, cerebrovascular disease, and aortic
aneurysm were also associated with an increased risk of a
postprocedure CES. On the other hand, there were no
significant differences in hypercholesterolemia and diabetes
mellitus between patients with and without CES. Plasma
CRP levels were significantly higher in patients with CES
than in those without it (0.7 vs. 2.4 mg/dl), which means
that higher CRP levels (CRP  1.0 mg/dl) are associated
with an increased risk for CES. In contrast, atrial fibrilla-
tion, the femoral artery approach, and the use of anticoagu-
lants were not associated with an increased risk of CES.
A multiple logistic regression analysis showed that an
elevated baseline CRP level was an independent predictor of
CES (Table 6). There was a 4.6-fold increase in the risk of
CES in those with pre-procedural increase (CRP 1.0
mg/dl) in plasma CRP levels. Plasma CRP level as a
Table 3. Clinical Features of CES
No CES
(n  1,761)
CES
(n  25) p Value
Blood eosinophil count
Baseline (/l), mean  SD 166  152 252  345  0.01
After (/l), mean  SD 200  365 470  496  0.01
Postprocedure value 500/l, n (%) 57 (3.2) 5 (20)  0.01
Death, n (%) 8 (0.5) 4 (16)  0.01
Abbreviation defined in Table 1.
Table 4. Clinical Features of Cholesterol Embolization Syndrome With and Without
Renal Dysfunction
Clinical Feature
Renal Dysfunction
p ValueYes (n  16) No (n  9)
Serum creatinine
Baseline (mg/dl), mean  SD 1.6  1.9 1.6  2.3 NS
After (mg/dl), mean  SD 3.3  3.2* 1.6  2.0 NS
Blood eosinophil count
Baseline (/l), mean  SD 220  272 302  449 NS
After (/l), mean  SD 535  592* 339  163 NS
Postprocedure value 500/l, n (%) 4 (25) 1 (11) NS
Outcome
Death, n 4 0 NS
New hemodialysis, n 4 0 NS
*p  0.05 compared with “Baseline.”
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continuous variable was also an independent risk factor of
CES (p  0.01).
DISCUSSION
This is the first prospective study to assess the incidence and
risk factors of CES in patients who have undergone cardiac
catheterization. The incidence of CES in our patient
population was 1.4%. Scolari et al. (9) retrospectively
reported that 15 of 16,223 vascular procedures were com-
plicated with CES, which was an incidence of 0.09%. In
contrast, the autopsy study reported that the overall preva-
lence of CES was 25% to 30% of patients after cardiac
catheterization (3). The prevalence in our prospective study
was intermediate between clinical and autopsy studies,
indicating that CES may occur in a subtle form after
intravascular procedures more often than that reported by
clinical manifestations (17).
Some case reports have shown a transient eosinophilia in
up to 80% of patients with CES (13,19). Similarly, in our
study population, the eosinophil counts were significantly
higher in CES patients than in non-CES patients before
and after cardiac catheterization. Furthermore, CES with
renal dysfunction showed greater increase of eosinophil
counts (from 220 to 535/l) compared to those patients
without renal dysfunction (from 302 to 339/l). All patients
who did not survive in the CES group had renal dysfunction
after catheterization, suggesting that renal insufficiency in
CES is critical. The present study showed an in-hospital
mortality of 16%. Most previous case reports of CES
described diffuse embolism and multiorgan failure, and
hence reported a mortality of 70% to 90% (14,20). The
difference between the present study and previous case series
may be due to the fact that our study population included
subtle cases of CES. Nonetheless, CES remained a condi-
tion associated with a high mortality.
This study identified independent pre-procedural predic-
tors of CES. The syndrome occurred more frequently in
patients with generalized atherosclerosis such as multiple-
vessel coronary disease and cerebrovascular disease shown by
univariate analysis. In particular, the variable identified as an
independent predictor of CES was a higher level of plasma
CRP, indicating an important association between systemic
inflammation and CES. Several studies including our own
have demonstrated an important role of inflammation in the
initiation and progression of atherosclerosis in human and
animal models (21–25). The mechanism of how inflamma-
tion leads to CES is unknown, but our present findings may
extend previous observation regarding inflammation as an
important cardiovascular risk factor (21–25). The vulnerable
Table 5. Univariate Analysis of Predictors for Postprocedure CES
Variables
No CES (n  1,761)
n (%)
CES (n  25)
n (%) p Value
Age (yrs), mean  SD 65  10 69  7 NS
75 years old 310 (18%) 4 (16%) NS
Male gender 1,152 (65%) 17 (68%) NS
Coronary artery disease 1,470 (83%) 20 (80%) NS
Acute coronary syndrome 354 (20%) 10 (40%) 0.02
Multivessel coronary artery disease 503 (28.5%) 13 (52.0%) 0.01
Atrial fibrillation 68 (3.9%) 1 (4.0%) NS
Left ventricular ejection fraction 45% 129 (7.3%) 2 (8.0%) NS
Hypercholesterolemia 662 (38%) 7 (28%) NS
Diabetes mellitus 550 (31%) 10 (42%) NS
Hypertension 867 (49%) 18 (75%) 0.03
Smoking 668 (38%) 14 (70%) 0.02
Cerebrovascular disease 112 (6%) 5 (20%) 0.01
Aortic aneurysm 54 (3%) 3 (12%) 0.01
Arteriosclerosis obliterans 75 (4%) 1 (4%) NS
Chronic renal failure with hemodialysis 46 (3%) 1 (4%) NS
Baseline serum creatinine (mg/dl), mean  SD 1.1  1.4 1.6  2.0 NS
2.0 mg/dl 60 (3%) 2 (8%) NS
C-reactive protein (mg/dl), mean  SD 0.7  1.7 2.4  3.0 0.01
1.0 mg/dl 202 (12%) 9 (36%) 0.01
Femoral approach 1,238 (70%) 20 (80%) NS
Coronary intervention 418 (24%) 8 (32%) NS
Anticoagulation 331 (19%) 5 (20%) NS
Abbreviation defined in Table 1.
Table 6. Multivariate Analysis of Predictors for Postprocedure
CES
Variable Odds Ratio
95% Confidence
Interval p Value
CRP 1.0 mg/dl 4.64 1.70–12.62 0.01
Aortic aneurysm 2.90 0.77–10.92 0.12
Smoking 2.67 0.99–7.22 0.08
Hypertension 2.55 0.96–6.75 0.07
Cerebrovascular disease 2.46 0.83–7.31 0.10
Multivessel coronary
artery disease
1.96 0.82–4.71 0.13
Acute coronary syndrome 1.87 0.78–4.51 0.20
CES  cholesterol embolization syndrome; CRP  C-reactive protein.
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atherosclerotic plaques contain a large amount of inflam-
matory cells, including macrophages (26), and such plaques
can be the source of cholesterol embolization. Elevated
levels of CRP may reflect enhanced immune or inflamma-
tory activity of atherosclerotic lesions in these patients. Our
findings may raise the possibility that strategies to minimize
vascular inflammation can reduce the occurrence of CES in
these patients. Treatment with HMG-CoA reductase in-
hibitors (statins) might be effective as a prophylaxis because
it can reduce systemic inflammation independent of de-
creasing plasma cholesterol levels (27–29). Further studies
are needed to investigate the usefulness of therapeutic
strategies for systemic inflammation in the prevention of
CES.
Several case reports have suggested that patients are more
likely to develop CES when they are anticoagulated; there-
fore, they are recommended to discontinue anticoagulation
when CES is suspected to be present (6,30). However,
studies suggesting a relation between anticoagulation and
CES were retrospective, and the results may have been
confounded by the use of anticoagulants to treat the
syndrome (31). Although anticoagulation may allow cho-
lesterol crystals to embolize freely, the present study did not
indicate any significant association between the use of
anticoagulants and CES. This is in agreement with a report
using transesophageal echocardiography, in which the risk
of clinically apparent CES was as low as 0.7% during
warfarin therapy in patients with aortic atheromas and atrial
fibrillation (32).
The abdominal aorta is one of the most heavily involved
areas with atherosclerotic plaques; therefore, procedures
involving mechanical injury by catheters to these regions
could potentially disrupt plaque material and induce CES
(4). Hence, we suspect that the frequency of CES is lowered
if procedures are performed via the brachial artery approach
(33); however, there were no significant differences in the
prevalence of the femoral approach with and without CES.
Therefore, it is possible that the ascending thoracic aorta
may potentially be a main embolic source of cholesterol
crystals causing CES.
Study limitations. Several limitations should be acknowl-
edged in this study. First, only the cutaneous manifestations
and renal impairment were used for the diagnosis of CES,
but histological confirmation was not required in this study.
Even though the biopsy of characteristic cutaneous and
renal lesions is helpful, less than 50% of patients show
typical findings (31). Furthermore, histological presence of
cholesterol embolization does not always result in clinically
specific CES (31). We thus consider that biopsy is useful
but not necessary to confirm the CES diagnosis.
Second, we defined renal impairment with CES as more
than 50% worsening of serum creatinine levels referred from
the previous study (11) and thereby we may have overesti-
mated its true frequency. Third, we employed serum creat-
inine data two weeks after the procedure because previous
case reports have shown that serum creatinine levels increase
several days after the procedure (16–18). Furthermore, the
decline in renal function immediately after the procedure
may not be due to CES but, more likely, to other causes
such as contrast nephrotoxicity or hypotension.
Moreover, there was no significant difference in the use of
angiotensin-converting enzyme inhibitors (ACEI) or angio-
tensin II receptor blockers (ARB) between CES and non-
CES groups in our study patients. Therefore, we consider
that the contribution of renal toxicity by ACEI or ARB may
be excluded. However, as we could not completely exclude
the possible contribution of some other causes, we diag-
nosed patients as possible CES if they had only renal
impairment without cutaneous signs.
Finally, although there was no significant difference in
the use of aspirin or statins at the time of procedure, we
could not provide data concerning the duration and the
dosage of aspirin or statins that were used before and after
cardiac catheterization in our study patients.
Conclusions. Finally, CES often occurs after a vascular
procedure in patients with systemic inflammation. It is not
a rare occurrence, but it is infrequently recognized. Clinical
manifestations range from mild to catastrophic. Elevated
baseline CRP levels can identify patients who are at
higher risk of post-catheterization CES. Better under-
standing and early recognition of this disease are expected
to reduce patient mortality and morbidity after cardiac
catheterization.
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